Cardiothoracic involvement by obstetric and gynecologic pathologic conditions creates a broad spectrum of clinical and radiologic manifestations, ranging from mild to critical. The authors describe the unique and often unrecognized …
Objective: To evaluate reproductive outcomes following fertility-sparing surgery for deep endometriosis (DE), specifically assessing the impact of bowel resection on spontaneous conception rates and the predictive value of the Endometriosis …
Pregnant women, as well as patients with endometriosis and some ovarian tumors, may experience a state of high estrogen levels. However, the role of high estrogen in platelet function and …
Among women pregnant after IVF/ICSI, do obstetric outcomes differ for women diagnosed with endometriosis and/or adenomyosis according to definitions by International Deep Endometriosis (IDEA) and the revised Morphological Uterus Sonographic …
Ovarian cysts are common during pregnancy, and dermoid cysts are common benign ovarian tumors, affecting approximately 0.3% of pregnancies, most often detected in the second trimester. Hormonal changes and pressure …
Endometriosis affects approximately 10% of reproductive-age women and has been associated with adverse obstetric outcomes. However, evidence guiding antenatal management remains limited and inconsistent.
Advanced maternal age (AMA) is a major challenge in reproductive medicine, compounded by coexisting conditions such as adenomyosis and endometriosis, which impair oocyte competence and endometrial receptivity. Prolonged gonadotropin-releasing hormone …
Neonatal uterine bleeding (NUB) has been hypothesized as a relatively common early-life event potentially linked to the later development of endometriosis through retrograde menstruation. However, its true prevalence and biological …
Polypoid endometriosis is a rare benign variant of endometriosis characterized by exuberant mass-forming endometrial tissue that can closely mimic aggressive pelvic malignancy on imaging. Although it most commonly affects peri- …
Elagolix is a short-acting oral gonadotropin-releasing hormone antagonist utilized for treating endometriosis-associated pain by rapidly suppressing gonadotropins and estradiol. Although well characterized in Western populations, clinical data regarding its use …